Keene & Associates Inc. Raises Stake in Smith & Nephew plc (NYSE:SNN)

Keene & Associates Inc. boosted its holdings in Smith & Nephew plc (NYSE:SNN) by 18.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 13,686 shares of the medical equipment provider’s stock after purchasing an additional 2,111 shares during the quarter. Keene & Associates Inc.’s holdings in Smith & Nephew were worth $336,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Principal Securities Inc. raised its stake in shares of Smith & Nephew by 87.6% in the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 691 shares during the period. R Squared Ltd purchased a new stake in Smith & Nephew during the 4th quarter worth $41,000. Hara Capital LLC increased its holdings in Smith & Nephew by 391.4% in the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 1,957 shares in the last quarter. GAMMA Investing LLC raised its position in Smith & Nephew by 31.8% in the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock valued at $73,000 after purchasing an additional 718 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Smith & Nephew by 74.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,025 shares of the medical equipment provider’s stock worth $94,000 after purchasing an additional 1,290 shares in the last quarter. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew Stock Up 1.0 %

Shares of Smith & Nephew stock opened at $25.95 on Wednesday. Smith & Nephew plc has a 1-year low of $23.65 and a 1-year high of $31.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The business has a 50-day moving average of $25.02 and a 200-day moving average of $27.37.

Wall Street Analysts Forecast Growth

SNN has been the subject of a number of recent research reports. Berenberg Bank lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. Deutsche Bank Aktiengesellschaft downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, StockNews.com cut shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.